Wegovy’s oral version of its injectable weight-loss drug is seeing tremendous interest, Novo Nordisk executive Dave Moore told FOX Business on Friday.Wegovy’s once-daily pill, an oral spin-off of its injectable weight loss medication, was approved in December 2025 by the Food and Drug Administration as the first oral GLP-1 drug and launched on U.S. markets Monday. "There are so many patients that have been on the sidelines just waiting because they didn't really see themselves treating with an injection," Moore, Novo Nordisk's executive vice president of U.S. Operations, said on "The Claman Co...

7 hours ago

On HALO